<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984578</url>
  </required_header>
  <id_info>
    <org_study_id>WoOCRC</org_study_id>
    <nct_id>NCT03984578</nct_id>
  </id_info>
  <brief_title>Window of Opportunity Study in Colorectal Cancer</brief_title>
  <official_title>Window of Opportunity Study With Neoadjuvant Pembrolizumab in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a window of opportunity translational study investigating the use of pre-operative&#xD;
      pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with radiologically-assessed locally advanced non-metastatic colorectal cancer will&#xD;
      receive the following treatment before surgery:&#xD;
&#xD;
      Colon cancers:&#xD;
&#xD;
      One cycle of CAPEOX chemotherapy Two cycles of Pembrolizumab on Day 1 (concurrent with CAPEOX&#xD;
      chemotherapy) and Day 22&#xD;
&#xD;
      Rectal cancers:&#xD;
&#xD;
      Following completion of chemo-radiotherapy with 5-fluorouracil (5-FU)/ capecitabine, patients&#xD;
      will receive 2 cycles of Pembrolizumab given 3 weeks apart&#xD;
&#xD;
      Pre-operative biopsy and surgical samples as well as blood will be collected for&#xD;
      translational studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour immune gene expression signature</measure>
    <time_frame>From time of first tumour biopsy before treatment to time of tumour resection performed 1-3 weeks after last dose of neoadjuvant treatment</time_frame>
    <description>Gene expression of key immune genes will be assayed and immune gene expression scores such as IFN-gamma Gene Expression Profile (GEP) signature score (Ayers et al. 2017 JCI) will be compared before (biopsy) and after treatment (surgery).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathology regression</measure>
    <time_frame>From time of first tumour biopsy before treatment to time of tumour resection performed 1-3 weeks after last dose of neoadjuvant treatment</time_frame>
    <description>A change in viable tumour after treatment will be measured by pathologist using tumour regression grade and major pathologic regression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune T-cell infiltration before and after treatment</measure>
    <time_frame>From time of first tumour biopsy before treatment to time of tumour resection performed 1-3 weeks after last dose of neoadjuvant treatment</time_frame>
    <description>The change in immune cell infiltration will be measured by pathologists through immunohistochemistry and/or immuno-fluorescence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative proportion/ percentage of the different immune cell states or immune cell types as inferred from single cell or bulk gene expression profiling</measure>
    <time_frame>At time of tumour resection performed 1-3 weeks after last dose of neoadjuvant treatment</time_frame>
    <description>Single cell RNA sequencing, bulk genomics &amp; bulk transcriptomics will be used to describe the enrichment of different immune cell states or cell types</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative distribution (percentage) of immune cells with specific expression of lineage markers</measure>
    <time_frame>At time of tumour resection performed 1-3 weeks after last dose of neoadjuvant treatment</time_frame>
    <description>Flow cytometry will be used to determine the proportions of immune cell types with specific lineage marker expression including CD45, CD4, CD8, PDL1 and LAG3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cell viability and cell death at fixed time points (e.g. 24 or 48 hours)</measure>
    <time_frame>At time of tumour resection performed 1-3 weeks after last dose of neoadjuvant treatment</time_frame>
    <description>Functional assays of immune cell immunoreactivity will be used to determine the proportion of target cell kill of paired immune cell and target cell</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Colon cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative CAPEOX 1 cycle Pre-operative Pembrolizumab 2 cycles with cycle 1 on Day 1 (concurrent with start of CAPEOX) and cycle 2 on Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal Cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following completion of neo-adjuvant chemo-radiotherapy, 2 cycles of pre-operative Pembrolizumab administered 3 weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAPEOX</intervention_name>
    <description>Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1</description>
    <arm_group_label>Colon cancers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion of 200mg on Day 1 and Day 22</description>
    <arm_group_label>Colon cancers</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine/ 5-FU</intervention_name>
    <description>Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation</description>
    <arm_group_label>Rectal Cancers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion of 200mg on Day 1 of each cycle</description>
    <arm_group_label>Rectal Cancers</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>Performed after all medical intervention</description>
    <arm_group_label>Colon cancers</arm_group_label>
    <arm_group_label>Rectal Cancers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adenocarcinoma of the colon (radiologic T4 and/or N2) OR rectal adenocarcinoma with&#xD;
             positive lymph nodes and/or threatened/positive circumferential resection margin&#xD;
             (CRM).&#xD;
&#xD;
          -  Patients with rectal adenocarcinoma must have completed neoadjuvant chemoradiation&#xD;
             therapy (or planned to receive neoadjuvant chemoradiation at point of recruitment).&#xD;
&#xD;
          -  Male/female participants who are at least 21 years of age on the day of signing&#xD;
             informed consent with histologically confirmed diagnosis of colorectal adenocarcinoma.&#xD;
&#xD;
          -  Female participants: A female participant is eligible to participate if she is not&#xD;
             pregnant, not breastfeeding, and at least one of the following conditions applies: a)&#xD;
             Not a woman of childbearing potential (WOCBP) OR b) A WOCBP who agrees to follow the&#xD;
             contraceptive guidance during the treatment period and for at least 120 days after the&#xD;
             last dose of study treatment.&#xD;
&#xD;
          -  The participant (or legally acceptable representative if applicable) provides written&#xD;
             informed consent for the trial.&#xD;
&#xD;
          -  Tumor evaluated to have sufficient tissue for translational studies&#xD;
&#xD;
          -  Have provided sufficient archival tumor tissue sample.&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
             Evaluation of ECOG is to be performed within 7 days prior to the date of&#xD;
             allocation/randomization.&#xD;
&#xD;
          -  Have adequate organ function as defined in the following table. Specimens must be&#xD;
             collected within 10 days prior to the start of study treatment.&#xD;
&#xD;
        Adequate Organ Function Laboratory&#xD;
&#xD;
          1. Absolute neutrophil count (ANC): ≥1500/μL&#xD;
&#xD;
          2. Platelets: ≥100 000/μL&#xD;
&#xD;
          3. Hemoglobin: ≥9.0 g/dL or ≥5.6 mmol/L&#xD;
&#xD;
          4. Creatinine OR Measured or calculated creatinine clearance: ≤1.5 × Upper 5. Limit of&#xD;
             Normal (ULN) OR ≥30 mL/min for participant with creatinine levels &gt;1.5 × institutional&#xD;
             ULN&#xD;
&#xD;
          5. Total bilirubin: ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total&#xD;
             bilirubin levels &gt;1.5 × ULN&#xD;
&#xD;
          6. Alanine Aminotransferase and Aspartate Aminotransferase: ≤2.5 × ULN&#xD;
&#xD;
          7. Coagulation - International normalized ratio (INR) OR prothrombin time (PT) Activated&#xD;
             partial thromboplastin time (aPTT): ≤1.5 × ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation of&#xD;
             subject number. If the urine test is positive or cannot be confirmed as negative, a&#xD;
             serum pregnancy test will be required.&#xD;
&#xD;
          -  Has any sign of distant metastases or need for emergency surgery.&#xD;
&#xD;
          -  Has past history of bowel perforation and abdominal fistula; a recent history of bowel&#xD;
             resection (within past 12 months) and/or patients with radiological evidence of active&#xD;
             bowel obstruction.&#xD;
&#xD;
          -  Has intercurrent illness, including but not limited to infections and unstable angina&#xD;
             pectoris.&#xD;
&#xD;
          -  Is on anticoagulation therapy (warfarin, low molecular weight heparin, rivaroxaban).&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,&#xD;
             CTLA-4, OX-40, and CD137).&#xD;
&#xD;
          -  Has received prior systemic anti-cancer therapy including investigational agents&#xD;
             within 1 year prior to allocation, except capecitabine as neoadjuvant therapy for&#xD;
             patients with rectal cancer.&#xD;
&#xD;
          -  Has received prior radiotherapy within 1 year of start of study treatment or planned&#xD;
             radiotherapy prior to surgery, except radiotherapy received as neoadjuvant therapy for&#xD;
             patients with rectal cancer.&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device for cancer within 1 year prior to the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study drug.&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 5 years.&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Has Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known&#xD;
             Hepatitis C virus infection.&#xD;
&#xD;
          -  Has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iain Tan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iain Tan, MD</last_name>
    <phone>+65 6436 8000</phone>
    <email>iain.tan.b.h@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sengkang General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>544886</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

